CIBC Asset Management
ITCI

CIBC Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CIBC Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,016
Closed -$398K – 1252
2025
Q1 		$398K Buy
3,016
+60
+2% +$7.48K ﹤0.01% 785
2024
Q4 		$247K Buy
2,956
+150
+5% +$12.3K ﹤0.01% 988
2024
Q3 		$205K Buy
+2,806
New +$211K ﹤0.01% 1099

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CIBC Asset Management's ITCI Position: Q2 2025 in Review

CIBC Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,016 shares — an estimated $398K sold.

CIBC Asset Management first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $398K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • CIBC Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • CIBC Asset Management sold 3,016 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $398K.
  • CIBC Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
  • CIBC Asset Management's Intra-Cellular Therapies Inc. position peaked at $398K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on CIBC Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.